Selective inhibition of histone deacetylase 6 promotes survival in a rat model of hemorrhagic shock

Journal of Trauma and Acute Care Surgery

Volumn 79, Issue 6, 2015, Pages 905-910

  Chang, Zhigang ^a,d   Li, Yongqing ^d   He, Wei ^b,d   Liu, Baoling ^d   Halaweish, Ihab ^d   Bambakidis, Ted ^d   Liang, Yingjian ^c,d   Alam, Hasan B ^d  

^a BEIJING HOSPITAL   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Hemorrhagic shock; high mobility group box 1; pyruvate dehydrogenase; rats; Tubastatin A

Indexed keywords

CASPASE 3; CYTOCHROME C; DIMETHYL SULFOXIDE; HIGH MOBILITY GROUP B1 PROTEIN; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; PYRUVATE DEHYDROGENASE; TUBASTATIN A; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ISOLATION; CELL LYSATE; CONTROLLED STUDY; DRUG INHIBITION; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; HEART; HEART MITOCHONDRION; HEMORRHAGIC SHOCK; LIVER; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; SEPTIC SHOCK; SURVIVAL; WESTERN BLOTTING; WISTAR KYOTO RAT; ANIMAL; DISEASE MODEL; METABOLISM; SHOCK, HEMORRHAGIC; SURVIVAL RATE;

ANIMALS; APOPTOSIS; BIOMARKERS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; HISTONE DEACETYLASE INHIBITORS; MALE; RATS; RATS, INBRED WKY; SHOCK, HEMORRHAGIC; SURVIVAL RATE;

EID: 84948958134     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0000000000000784     Document Type: Article

References (43)

1. Rhee P, Joseph B, Pandit V, Aziz H, Vercruysse G, Kulvatunyou N, Friese RS,. Increasing trauma deaths in the United States. Ann Surg. 2014; 260 (1): 13-21.
2. Wilson M, Davis DP, Coimbra R,. Diagnosis and monitoring of hemorrhagic shock during the initial resuscitation of multiple trauma patients: a review. J Emerg Med. 2003; 24 (4): 413-422.
3. Li Y, Alam HB,. Creating a pro-survival and anti-inflammatory phenotype by modulation of acetylation in models of hemorrhagic and septic shock. Adv Exp Med Biol. 2012; 710: 107-133.
4. Crouser ED,. Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion. 2004; 4 (5-6): 729-741.
5. Fink MP,. Cytopathic hypoxia. Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. Crit Care Clin. 2001; 17 (1): 219-237.
6. Andersen LW, Liu X, Peng TJ, Giberson TA, Khabbaz KR, Donnino MW,. Pyruvate dehydrogenase activity and quantity decreases after coronary artery bypass grafting: a prospective observational study. Shock. 2015; 43 (3): 250-254.
7. Merante F, Mickle DA, Weisel RD, Li RK, Tumiati LC, Rao V, Williams WG, Robinson BH,. Myocardial aerobic metabolism is impaired in a cell culture model of cyanotic heart disease. Am J Physiol. 1998; 275 (5 Pt 2): H1673-H1681.
8. Storey KB,. Regulation of hypometabolism: insights into epigenetic controls. J Exp Biol. 2015; 218 (Pt 1): 150-159.
9. Guan KL, Xiong Y,. Regulation of intermediary metabolism by protein acetylation. Trends Biochem Sci. 2011; 36 (2): 108-116.
10. Gonzales E, Chen H, Munuve R, Mehrani T, Britten-Webb J, Nadel A, Alam HB, Wherry D, Burris D, Koustova E,. Valproic acid prevents hemorrhage-associated lethality and affects the acetylation pattern of cardiac histones. Shock. 2006; 25 (4): 395-401.
11. Liu Z, Li Y, Chong W, Deperalta DK, Duan X, Liu B, Halaweish I, Zhou P, Alam HB,. Creating a prosurvival phenotype through a histone deacetylase inhibitor in a lethal two-hit model. Shock. 2014; 41 (2): 104-108.
12. Luo HM, Hu S, Bai HY, Wang HB, Du MH, Lin ZL, Ma L, Wang H, Lv Y, Sheng ZY,. Valproic acid treatment attenuates caspase-3 activation and improves survival after lethal burn injury in a rodent model. J Burn Care Res. 2014; 35 (2): e93-e98.
13. Ji MH, Li GM, Jia M, Zhu SH, Gao DP, Fan YX, Wu J, Yang JJ,. Valproic acid attenuates lipopolysaccharide-induced acute lung injury in mice. Inflammation. 2013; 36 (6): 1453-1459.
14. Strahl BD, Allis CD,. The language of covalent histone modifications. Nature. 2000; 403 (6765): 41-45.
15. Parbin S, Kar S, Shilpi A, Sengupta D, Deb M, Rath SK, Patra SK,. Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem. 2014; 62 (1): 11-33.
16. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ,. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 2011; 32 (7): 335-343.
17. Li Y, Alam HB,. Modulation of acetylation: creating a pro-survival and anti-inflammatory phenotype in lethal hemorrhagic and septic shock. J Biomed Biotechnol. 2011; 2011: 523481.
18. Valenzuela-Fernandez A, Cabrero JR, Serrador JM, Sanchez-Madrid F,. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 2008; 18 (6): 291-297.
19. de Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H, Bradner JE, Mazitschek R, Kozikowski AP, Matthias P, Hancock WW,. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol. 2011; 31 (10): 2066-2078.
20. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP,. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005; 18 (5): 601-607.
21. Serrador JM, Cabrero JR, Sancho D, Mittelbrunn M, Urzainqui A, Sanchez-Madrid F,. HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. Immunity. 2004; 20 (4): 417-428.
22. Rivieccio MA, Brochier C, Willis DE, Walker BA, D'Annibale MA, McLaughlin K, Siddiq A, Kozikowski AP, Jaffrey SR, Twiss JL, Ratan RR, Langley B,. HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci USA. 2009; 106 (46): 19599-19604.
23. Zhao T, Li Y, Bronson RT, Liu B, Velmahos GC, Alam HB,. Selective histone deacetylase-6 inhibition attenuates stress responses and prevents immune organ atrophy in a lethal septic model. Surgery. 2014; 156 (2): 235-242.
24. Zhao T, Li Y, Liu B, Halaweish I, Mazitschek R, Alam HB,. Selective inhibition of histone deacetylase 6 alters the composition of circulating blood cells in a lethal septic model. J Surg Res. 2014; 190 (2): 647-654.
25. Lee HB, Blaufox MD,. Blood volume in the rat. J Nucl Med. 1985; 26 (1): 72-76.
26. Minucci S, Pelicci PG,. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6 (1): 38-51.
27. Wang L, de Zoeten EF, Greene MI, Hancock WW,. Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov. 2009; 8 (12): 969-981.
28. Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ, Humbert S, Saudou F,. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci. 2007; 27 (13): 3571-3583.
29. Kazantsev AG, Thompson LM,. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov. 2008; 7 (10): 854-868.
30. Singer M,. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence. 2014; 5 (1): 66-72.
31. Levy B,. Lactate and shock state: the metabolic view. Curr Opin Crit Care. 2006; 12 (4): 315-321.
32. Patel TB, Olson MS,. Regulation of pyruvate dehydrogenase complex in ischemic rat heart. Am J Physiol. 1984; 246 (6 Pt 2): H858-H864.
33. Bogaert YE, Sheu KF, Hof PR, Brown AM, Blass JP, Rosenthal RE, Fiskum G,. Neuronal subclass-selective loss of pyruvate dehydrogenase immunoreactivity following canine cardiac arrest and resuscitation. Exp Neurol. 2000; 161 (1): 115-126.
34. Lewandowski ED, Johnston DL,. Reduced substrate oxidation in postischemic myocardium: 13C and 31P NMR analyses. Am J Physiol. 1990; 258 (5 Pt 2): H1357-H1365.
35. Campana L, Bosurgi L, Rovere-Querini P,. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol. 2008; 20 (5): 518-523.
36. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A,. HMGB1: endogenous danger signaling. Mol Med. 2008; 14 (7-8): 476-484.
37. Scaffidi P, Misteli T, Bianchi ME,. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002; 418 (6894): 191-195.
38. Kim JY, Park JS, Strassheim D, Douglas I, Diaz del Valle F, Asehnoune K, Mitra S, Kwak SH, Yamada S, Maruyama I, Ishizaka A, Abraham E,. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am J Physiol Lung Cell Mol Physiol. 2005; 288 (5): L958-L965.
39. Gwak GY, Moon TG, Lee DH, Yoo BC,. Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway. World J Gastroenterol. 2012; 18 (7): 679-684.
40. Schägger H,. Respiratory chain supercomplexes of mitochondria and bacteria. Biochim Biophys Acta. 2002; 1555 (1-3): 154-159.
41. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X,. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997; 91 (4): 479-489.
42. Liu X, Kim CN, Yang J, Jemmerson R, Wang X,. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996; 86 (1): 147-157.
43. Van Way CW 3rd, Dhar A, Morrison DC, Longorio MA, Maxfield DM,. Cellular energetics in hemorrhagic shock: restoring adenosine triphosphate to the cells. J Trauma. 2003; 54 (Suppl 5): S169-S176.